Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
VRDN
VRDN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VRDN News
Viridian's Lumvoa Therapy for Thyroid Eye Disease Set to Launch
Jun 30 2026
Yahoo Finance
U.S. Stocks Close Higher, Led by Technology Gains
Jun 29 2026
NASDAQ.COM
US Stocks Rise, Led by Technology Sector Gains
Jun 29 2026
NASDAQ.COM
US Stocks Rise, Led by Technology Sector Gains
Jun 29 2026
NASDAQ.COM
Universe Pharmaceuticals Acquires Best Praise International
Jun 29 2026
Newsfilter
FDA Approves Viridian's Lumvoa for Thyroid Eye Disease
Jun 29 2026
Newsfilter
U.S. Stock Futures Rise, Led by Tech Gains Amid Easing Middle East Tensions
Jun 29 2026
Newsfilter
U.S. Stock Futures Rise as Investor Confidence Rebounds
Jun 29 2026
seekingalpha
Viridian Launches Lumvoa for Thyroid Eye Disease Following FDA Approval
Jun 27 2026
seekingalpha
Viridian Receives FDA Approval for Lumvoa to Treat Thyroid Eye Disease
Jun 27 2026
NASDAQ.COM
FDA Approves Lumvoa for Thyroid Eye Disease Treatment
Jun 26 2026
stocktwits
FDA Approves Lumvoa for Thyroid Eye Disease Treatment
Jun 26 2026
Newsfilter
HighVista Strategies Reduces Stake in Viridian Therapeutics
May 17 2026
Fool
HighVista Strategies Cuts Stake in Viridian Therapeutics by $7 Million
May 17 2026
Yahoo Finance
Viridian Therapeutics Raises $350M Through Upsized Public Offerings
May 07 2026
seekingalpha
Viridian Therapeutics Completes $225 Million Financing
May 07 2026
Newsfilter
Show More News
